1 week Ago By ABMN Staff
Legal & General Group Plc decreased its stake in Establishment Labs Holdings Inc. ( NASDAQ:ESTA – Free Report ) by 12.4% in the fourth quarter, HoldingsChannel.
com reports. The institutional investor owned 19,548 shares of the company’s stock after selling 2,757 shares during the period. Legal & General Group Plc’s holdings in Establishment Labs were worth $901,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC lifted its holdings in Establishment Labs by 9,643.3% in the 3rd quarter.
Barclays PLC now owns 31,471 shares of the company’s stock worth $1,362,000 after purchasing an additional 31,148 shares in the last quarter. SkyView Investment Advisors LLC lifted its holdings in shares of Establishment Labs by 30.5% in the third quarter.
SkyView Investment Advisors LLC now owns 12,000 shares of the company’s stock worth $519,000 after buying an additional 2,805 shares in the last quarter. Assenagon Asset Management S.A.
purchased a new position in shares of Establishment Labs in the fourth quarter worth $12,898,000. R Squared Ltd purchased a new position in shares of Establishment Labs in the fourth quarter worth $36,000. Finally, Handelsbanken Fonder AB lifted its holdings in shares of Establishment Labs by 32.
3% in the fourth quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company’s stock worth $378,000 after buying an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 72.
91% of the company’s stock. Analysts Set New Price Targets Several research firms have recently commented on ESTA. Needham & Company LLC began coverage on shares of Establishment Labs in a report on Monday, April 14th.
They issued a “hold” rating on the stock. Stephens reissued an “overweight” rating and issued a $52.00 target price on shares of Establishment Labs in a report on Thursday, March 6th.
Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Establishment Labs currently has an average rating of “Moderate Buy” and a consensus target price of $57.
40. Establishment Labs Price Performance ESTA stock opened at $29.97 on Monday.
Establishment Labs Holdings Inc. has a 52 week low of $26.56 and a 52 week high of $60.
12. The company has a quick ratio of 2.29, a current ratio of 3.
62 and a debt-to-equity ratio of 5.94. The company has a fifty day simple moving average of $36.
09 and a two-hundred day simple moving average of $39.21. The firm has a market capitalization of $864.
51 million, a P/E ratio of -11.62 and a beta of 0.77.
Establishment Labs ( NASDAQ:ESTA – Get Free Report ) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.
64) by ($0.34). Establishment Labs had a negative net margin of 46.
13% and a negative return on equity of 184.55%. The business had revenue of $44.
51 million for the quarter, compared to the consensus estimate of $44.45 million. Analysts anticipate that Establishment Labs Holdings Inc.
will post -2.41 earnings per share for the current fiscal year. About Establishment Labs ( Free Report ) Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery.
The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. Read More Want to see what other hedge funds are holding ESTA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Establishment Labs Holdings Inc. ( NASDAQ:ESTA – Free Report ). Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.
com's FREE daily email newsletter ..
